Circulating Tumor DNA Methylation Is a Biomarker of Poor Recurrence-free Survival in Locally-Advanced Rectal Cancer.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-04-01 DOI:10.21873/anticanres.17537

Kiichi Sugimoto, Takahiro Irie, Hirotaka Momose, Saki Kochi, Miyuki Toake, Yuki Tsuchiya, Ryoichi Tsukamoto, Kumpei Honjo, Shun Ishiyama, Makoto Takahashi, Robert M Hoffman, Kazuhiro Sakamoto

{"title":"Circulating Tumor DNA Methylation Is a Biomarker of Poor Recurrence-free Survival in Locally-Advanced Rectal Cancer.","authors":"Kiichi Sugimoto, Takahiro Irie, Hirotaka Momose, Saki Kochi, Miyuki Toake, Yuki Tsuchiya, Ryoichi Tsukamoto, Kumpei Honjo, Shun Ishiyama, Makoto Takahashi, Robert M Hoffman, Kazuhiro Sakamoto","doi":"10.21873/anticanres.17537","DOIUrl":null,"url":null,"abstract":"Background/aim: The aim of this study was to investigate locus-specific circulating-tumor DNA (ctDNA) methylation for predicting long-term outcomes of locally-advanced rectal cancer (LARC) after resection.Materials and methods: In the present study, there were 50 patients without preoperative treatment and 35 patients with preoperative treatment. Methylation analyses for checkpoint with forkhead and ring finger domains (CHFR), sex-determining region Y-box transcription factor 11 (SOX11) and cysteine dioxygenase type 1 (CDO1) used DNA extracted from plasma ctDNA at the time of resection of the primary tumor with curative-intent surgery.Results: Highly-methylated SOX11 in ctDNA was found to be a biomarker of reduced recurrence-free survival (RFS) in LARC. In multivariate analysis, highly methylated SOX11 was an independent prognostic factor for reduced RFS in the group without preoperative treatment.Conclusion: The present study demonstrates that elevated ctDNA methylation of the SOX11 gene is a biomarker for reduced RFS after curative-intent resection of LARC. Patients with high ctDNA methylation of the SOX11 gene may not be optimal candidates for LARC resection. A prospective study is necessary to further validate SOX11 ctDNA methylation as a biomarker for RFS of patients with LARC.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1559-1573"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17537","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The aim of this study was to investigate locus-specific circulating-tumor DNA (ctDNA) methylation for predicting long-term outcomes of locally-advanced rectal cancer (LARC) after resection.

Materials and methods: In the present study, there were 50 patients without preoperative treatment and 35 patients with preoperative treatment. Methylation analyses for checkpoint with forkhead and ring finger domains (CHFR), sex-determining region Y-box transcription factor 11 (SOX11) and cysteine dioxygenase type 1 (CDO1) used DNA extracted from plasma ctDNA at the time of resection of the primary tumor with curative-intent surgery.

Results: Highly-methylated SOX11 in ctDNA was found to be a biomarker of reduced recurrence-free survival (RFS) in LARC. In multivariate analysis, highly methylated SOX11 was an independent prognostic factor for reduced RFS in the group without preoperative treatment.

Conclusion: The present study demonstrates that elevated ctDNA methylation of the SOX11 gene is a biomarker for reduced RFS after curative-intent resection of LARC. Patients with high ctDNA methylation of the SOX11 gene may not be optimal candidates for LARC resection. A prospective study is necessary to further validate SOX11 ctDNA methylation as a biomarker for RFS of patients with LARC.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.